Trial · NCT05571111
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of metaphase II (MII) oocytes | On the day of oocyte retrieval (2 days after triggering) | |
| Secondary | Number of oocytes retrieved | On the day of oocyte retrieval (2 days after triggering) | |
| Secondary | Number of fertilised (2 pronuclei) oocytes | On day 1 insemination (3 days after triggering) | |
| Secondary | Number and quality of embryos on day 3 after oocyte retrieval | Day 3 after insemination (5 days after triggering) | |
| Secondary | Number and quality of blastocysts on day 5 after oocyte retrieval | Day 5 after insemination (7 days after triggering) | |
| Secondary | Serum hormone concentrations of progesterone | Blood samples for analysis of circulating concentrations of progesterone will be drawn at several visits from day of triggering up to 22 days after triggering | |
| Secondary | Serum hormone concentrations of 17-OH-progesterone | Blood samples for analysis of circulating concentrations of 17-OH-progesterone will be drawn at several visits from day of triggering up to 22 days after triggering | |
| Secondary | Serum hormone concentrations of estradiol | Blood samples for analysis of circulating concentrations of estradiol will be drawn at several visits from day of triggering up to 22 days after triggering | |
| Secondary | Serum hormone concentrations of follicle stimulating hormone (FSH) | Blood samples for analysis of circulating concentrations of follicle stimulating hormone (FSH) will be drawn at several visits from day of triggering up to 22 days after triggering | |
| Secondary | Serum hormone concentrations of luteinising hormone (LH) | Blood samples for analysis of circulating concentrations of luteinising hormone (LH) will be drawn at several visits from day of triggering up to 22 days after triggering | |
| Secondary | Positive βhCG (positive serum βhCG test 13-15 days after transfer) | 20-22 days after triggering | |
| Secondary | Clinical pregnancy (at least one gestational sac 5-6 weeks after transfer) | 6-7 weeks after triggering | |
| Secondary | Vital pregnancy (at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer) | 6-7 weeks after triggering | |
| Secondary | Ongoing pregnancy (at least one intrauterine viable fetus 10-11 weeks after transfer) | 11-12 weeks after triggering | |
| Secondary | Serum hCG concentrations at end-of-stimulation, the day after triggering, at oocyte retrieval, on day 5 after oocyte retrieval (transfer), and on day 7-9 after oocyte retrieval (mid luteal phase) | Blood samples for analysis of circulating concentrations of hCG will be drawn at several visits from day of triggering up to 9-11 days after triggering | |
| Secondary | Ovarian hyperstimulation syndrome (OHSS), overall and by timing, grade, and severity | ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation (late OHSS) | Early OHSS is defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Late OHSS is defined as OHSS with onset \>9 days after triggering of final follicular maturation. |
| Secondary | Injection site reactions (redness, pain, itching, swelling, and bruising) assessed by the subject following administration of investigational medicinal product (IMP) | Immediately, 30 minutes, and 24 hours after injection | |
| Secondary | Treatment-induced anti-hCG antibodies, overall as well as with neutralising capacity | Day of triggering up until 19-28 days after triggering | |
| Secondary | Multi-fetal gestation | From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering) | |
| Secondary | Biochemical pregnancy | From day after blastocyst transfer (7 days after triggering) up until ongoing pregnancy (11-12 weeks after triggering) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05571111/registered